Fetal lung maturation with corticosteroids, a complex situation in the mother with diabetes
DOI:
https://doi.org/10.47196/diab.v52i3.128Keywords:
fetal lung maturation, corticosteroids, gestational diabetes, respiratory distress síndromeAbstract
Lungs maturation with corticosteroids has been a very significant advance in the prevention of respiratory complications of premature infants, becoming a milestone in the history of modern medicine.
It is known that the children of mothers with gestational or pre-gestational diabetes have a higher incidence of respiratory distress syndrome of the newborn, so they are benefited by this medical practice. Strict metabolic control during this treatment is essential through the implementation of glycemic monitoring and insulin infusion protocols, since the hyperglycemic effect of corticosteroids could cause an inhibition of surfactant production, which would impede its effect on lung maturation not obtaining, consequently, the beneficial effects at the respiratory level. For this reason, different treatment schemes have been established in order to obtain the desired results, avoiding or minimizing the risks.
References
Schwarcz RL, Duverges CA, Díaz AG, et al. Obstetricia. 6ta. Edición. Buenos Aires: Editorial El Ateneo, 2005; cap. 2:24-25.
Iñiguez F, Sánchez I. Desarrollo pulmonar. Revista Neumonología Pediátrica, Sociedad Chilena de Neumología Pediátrica 2008; Vol 3, 2:148-155.
Fetal lung maturity. ACOG Practice Bulletin Nº 97. American College of Obstetricians and Gynecologist. Obstet Gynecol 2008; 112:117-26.
Delgado J, Greene M, Winkelman J, et al. Comparison of disaturated phosphatidylcholine and fetal lung maturity surfactant/albumin ratio in diabetic and nondiabetic pregnancies. Am J Clin Pathol 2000; 113:233-239.
Melanson SE, Jarolim P, Mc Elrath TF, et al. Fetal lung maturity testing in diabetic mothers. Lab Med 2007; 38:553.
Consenso de diabetes. Recopilación, actualización y recomendaciones para el diagnóstico y tratamiento de la diabetes gestacional. FASGO 2012 Sep; Vol 11, Nº 2.
Cordero L, Treuer SH, Landon MB, et al. Management of infants of diabetic mothers. Arch Pediatr Adolesc Med 1998; 152(3):249.
Moore TR. A comparison of amniotic fluid fetal pulmonary phospholipids in normal and diabetic pregnancy. Am J Obstet Gynecol 2002 Apr; 186 (4): 641-50.
Piper JM, Xenakis EM, Langer O. Delayed appearance of pulmonary maturation markers is associated with poor glucose control in diabetic pregnancies. Matern Fetal Med 1998; 7(3):148.
Piper JM. Lung maturation in diabetes in pregnancy: if and when to test. Semin Perinatol 2002 Jun; 26(3):206-9.
Piazze JJ, Anceschi MM, Maranghi L, et al. Fetal lung maturity in pregnancies complicated by insulin-dependent and gestational diabetes: a matched cohort study. Eur J Obstet Gynecol Reprod Biol 1999 Apr; 83(2):145-50.
Carlson KS, Smith BT, Post M. Insulin acts on the fibroblast to inhibit glucocorticoid stimulation of lung maturation. J Appl Physiol 1984; 57:1577-1579.
Guideline for the use of antenatal corticosteroids for fetal maturation. J Perinat Med 2008; 36:191-196.
Antenatal corticosteroids to reduce neonatal morbidity and mortality. Green-top Guideline Nº 7 October 2010. Royal College of Obstetricians and Gynaecologists.
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017 Mar 21; Issue 3.
Roberts D, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; (3).
Brownfoot FC, Crowther CA, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth (Review).The Cochrane Library 2008; Issue 4.
Lee BH, Stoll BJ, McDonald SA, Higgins RD. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006;117;1503
Baud O, Foix-L’Helias L, Kaminski M, et al. Antenatal
glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341:1190-6.
Gurbuz A, Karateke A, Ozturk G et al. Is 1-hour glucose screening test reliable after a short-term administration of antenatal betamethasone? Am J Perinatol 2004 Oct; 21(7):415-20.
Mastrobattista JM, Patel N, Monga M. Betamethasone alteration of the one-hour glucose challenge test in pregnancy. J Reprod Med 2001;46:83-86.
JianYun X, Zhaoxia L, Yun C, et al. Changes in maternal glucose metabolism after the administration of dexamethasone for fetal lung development. Int J Endocrinol 2012; 2012.
Foglia LM, Deering SH, Lim E, et al. Maternal glucose levels after dexamethasone for fetal lung development in twin vs singleton pregnancies. Am J Obstet Gynecol 2008 Oct; 199 (4):380.
Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol 2012 May; 29 (5):335-8.
Bedalov A, Balasubramanyam A. Glucocorticoid-induced ketoacidosis in gestational diabetes: sequela of the acute treatment of preterm labor. A case report. Diabetes Care 1997 Jun; 20 (6):922-4.
Iafusco D, Stoppoloni F, Salvia G, et al. Use of real time continuous glucose monitoring and intravenous insulin in type 1 diabetic mothers to prevent respiratory distress and hypoglycaemia in infants. BMC Pregnancy Childbirth 2008, 8:23.
Warburton D. Chronic hyperglycemia with secondary hyperinsulinemia inhibits the maturational response of fetal lamb lungs to cortisol. J Clin Invest 1983; 433-440.
Ramírez-Torres MA, Pérez-Monter SE, Espino y Sosa S, et al. Efecto de la betametasona en la glucemia de diabéticas embarazadas en riesgo de nacimiento pretérmino. Ginecol Obstet Mex 2011; 79(9):565-571.
Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol 2012; 29:335-338.
Antenatal corticosteroids to reduce neonatal morbidity and mortality. Green-top Guideline N1 7. October 2010. Royal College of Obstetricians and Gynaecologists.
Recomendaciones para gestantes con diabetes pregestacional. Conclusiones del Consenso reunido por convocatoria del Comité de Diabetes y Embarazo de la SAD. Octubre 2009.
Consenso Latinoamericano de Diabetes y Embarazo. ALAD noviembre de 2007.
Mathiesen ER, Christensen AB, Hellmuth E, et al. Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm (correction of analgoritm). Acta Obstet Gynecol Scand 2002 Sep; 81(9):835-9.
Kaushal K, Gibson JM, Railton A, et al. A protocol for improved glycaemic control following corticosteroid therapy in diabetic pregnancies. Diabet Med 2003 Jan; 20 (1):73-5.
Dalziel SR, Liang A, Parag V, et al. Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics 2004 Sep; 114(3):e373-7.
Dalziel SR, Rea HH, Walker NK, et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax 2006 Aug; 61(8):678-83.
Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomized controlled trial. Lancet 2005; 365: 1856-62.
Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 2005 Sep 24; 331(7518):665.
Dalziel SR, Fenwick S, Cundy T, et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. J Bone Miner Res 2006; 21:1175-1186.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
